| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Anti-Tac(Fv)-PE38, also called LMB-2, is a very active recombinant immunotoxin that has produced eight responses, including a durable clinical complete remission in a recently completed phase I trial of leukemias and lymphomas. Dose escalation was limited by liver toxicity. We have noted that the Fv of anti-Tac has an isoelectric point (pI) of 10.2. We hypothesize that the overall positive charge on the Fv portion of anti-Tac(Fv)-PE38 contributes to nonspecific binding to liver cells and results in dose-limiting liver toxicity. We have used a mouse model to investigate the basis of this toxicity and found that lowering the pI of the Fv of anti-Tac from 10.2 to 6.82 by selective mutation of surface residues causes a 3-fold decrease in animal toxicity and hepatic necrosis. This change in pI did not significantly alter the CD25 binding affinity, the cytotoxic activity toward target cells, or antitumor activity, resulting in a 3-fold improvement in the therapeutic index. If this decreased toxicity occurs in humans, it should greatly increase the clinical utility of this immunotoxin.
This article has been cited by other articles:
|
|
 |
|
  J. E. Weldon, L. Xiang, O. Chertov, I. Margulies, R. J. Kreitman, D. J. FitzGerald, and I. Pastan A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity Blood, April 16, 2009; 113(16): 3792 - 3800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Onda, S. Nagata, D. J. FitzGerald, R. Beers, R. J. Fisher, J. J. Vincent, B. Lee, M. Nakamura, J. Hwang, R. J. Kreitman, et al. Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients J. Immunol., December 15, 2006; 177(12): 8822 - 8834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Kennedy, T. K. Bera, Q.-C. Wang, M. Gallo, W. Wagner, M. G. Lewis, E. A. Berger, and I. Pastan Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques J. Leukoc. Biol., November 1, 2006; 80(5): 1175 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Chang, P. Sapra, S. S. Vanama, H. J. Hansen, I. D. Horak, and D. M. Goldenberg Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin Blood, December 15, 2005; 106(13): 4308 - 4314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsusaka, J. Xin, S. Niwa, K. Kobayashi, A. Akatsuka, H. Hashizume, Q.-c. Wang, I. Pastan, A. B. Fogo, and I. Ichikawa Genetic Engineering of Glomerular Sclerosis in the Mouse via Control of Onset and Severity of Podocyte-Specific Injury J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1013 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Onda, Q.-c. Wang, H.-f. Guo, N.-K. V. Cheung, and I. Pastan In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma Cancer Res., February 15, 2004; 64(4): 1419 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagata, M. Onda, Y. Numata, K. Santora, R. Beers, R. J. Kreitman, and I. Pastan Novel Anti-CD30 Recombinant Immunotoxins Containing Disulfide-stabilized Fv Fragments Clin. Cancer Res., July 1, 2002; 8(7): 2345 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Onda, S. Nagata, Y. Tsutsumi, J. J. Vincent, Q.-c. Wang, R. J. Kreitman, B. Lee, and I. Pastan Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity Cancer Res., July 1, 2001; 61(13): 5070 - 5077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Onda, M. Willingham, Q.-c. Wang, R. J. Kreitman, Y. Tsutsumi, S. Nagata, and I. Pastan Inhibition of TNF-{alpha} Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2 J. Immunol., December 15, 2000; 165(12): 7150 - 7156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. V. J. M. van Oosterhout, L. van Emst, A. V. M. B. Schattenberg, W. J. M. Tax, D. J. Ruiter, H. Spits, F. M. Nagengast, R. Masereeuw, S. Evers, T. de Witte, et al. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease Blood, June 15, 2000; 95(12): 3693 - 3701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tsutsumi, M. Onda, S. Nagata, B. Lee, R. J. Kreitman, and I. Pastan Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity PNAS, July 18, 2000; 97(15): 8548 - 8553. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
